Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
M Cohenuram, MW Saif - Anti-cancer drugs, 2007 - journals.lww.com
Panitumumab (formerly known as ABX-EGF) is the first fully human monoclonal antibody to
epidermal growth factor receptor to enter clinical trials for the treatment of solid tumors. Like
cetuximab (Erbitux; BMS), it is directed against the extracellular ligand-binding domain of the
receptor and results in blockade of the essential downstream signaling pathways that are
known to govern apoptosis, proliferation and differentiation of both normal and neoplastic
cell types in a wide array of tissues. It has a very high affinity for epidermal growth factor …
epidermal growth factor receptor to enter clinical trials for the treatment of solid tumors. Like
cetuximab (Erbitux; BMS), it is directed against the extracellular ligand-binding domain of the
receptor and results in blockade of the essential downstream signaling pathways that are
known to govern apoptosis, proliferation and differentiation of both normal and neoplastic
cell types in a wide array of tissues. It has a very high affinity for epidermal growth factor …